JP2023502625A5 - - Google Patents
Info
- Publication number
- JP2023502625A5 JP2023502625A5 JP2022527937A JP2022527937A JP2023502625A5 JP 2023502625 A5 JP2023502625 A5 JP 2023502625A5 JP 2022527937 A JP2022527937 A JP 2022527937A JP 2022527937 A JP2022527937 A JP 2022527937A JP 2023502625 A5 JP2023502625 A5 JP 2023502625A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- peptide
- ras
- molecule
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025140331A JP2025176716A (ja) | 2019-11-15 | 2025-08-26 | 共有新抗原を標的にする抗原結合タンパク質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936303P | 2019-11-15 | 2019-11-15 | |
| US62/936,303 | 2019-11-15 | ||
| US202063030774P | 2020-05-27 | 2020-05-27 | |
| US63/030,774 | 2020-05-27 | ||
| PCT/US2020/060605 WO2021097365A2 (en) | 2019-11-15 | 2020-11-13 | Antigen-binding proteins targeting shared neoantigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025140331A Division JP2025176716A (ja) | 2019-11-15 | 2025-08-26 | 共有新抗原を標的にする抗原結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502625A JP2023502625A (ja) | 2023-01-25 |
| JP2023502625A5 true JP2023502625A5 (enExample) | 2023-11-21 |
Family
ID=75912393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527937A Pending JP2023502625A (ja) | 2019-11-15 | 2020-11-13 | 共有新抗原を標的にする抗原結合タンパク質 |
| JP2025140331A Pending JP2025176716A (ja) | 2019-11-15 | 2025-08-26 | 共有新抗原を標的にする抗原結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025140331A Pending JP2025176716A (ja) | 2019-11-15 | 2025-08-26 | 共有新抗原を標的にする抗原結合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230041030A1 (enExample) |
| EP (1) | EP4058484A4 (enExample) |
| JP (2) | JP2023502625A (enExample) |
| KR (1) | KR20220098379A (enExample) |
| CN (1) | CN115175934A (enExample) |
| AU (1) | AU2020384374A1 (enExample) |
| CA (1) | CA3157411A1 (enExample) |
| IL (1) | IL292535A (enExample) |
| WO (1) | WO2021097365A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| CA3127673A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2022082030A2 (en) | 2020-10-15 | 2022-04-21 | Gritstone Bio, Inc. | Antigen-binding proteins and related methods of use |
| WO2022155503A1 (en) | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2023288203A2 (en) * | 2021-07-12 | 2023-01-19 | Ludwig Institute For Cancer Research Ltd | T cell receptors specific for tumor-associated antigens and methods of use thereof |
| EP4401766A4 (en) * | 2021-09-17 | 2025-10-29 | Seattle Project Corp | Neo-antigenic anti-Kras therapies |
| CN118525037A (zh) * | 2021-10-29 | 2024-08-20 | 侯亚非 | 识别ctnnb1中s37f突变的t细胞受体及其应用 |
| WO2023086435A1 (en) * | 2021-11-10 | 2023-05-19 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting q61-comprising ras mutations and uses thereof |
| EP4466283A1 (en) * | 2022-01-21 | 2024-11-27 | T-Knife GmbH | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| WO2023173024A2 (en) * | 2022-03-10 | 2023-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of coronary artery disease by reducing activity of cross-reactive t cells |
| WO2023220718A1 (en) * | 2022-05-13 | 2023-11-16 | Fred Hutchinson Cancer Center | Binding proteins specific for ras neoantigens and uses thereof |
| WO2024036166A1 (en) * | 2022-08-08 | 2024-02-15 | The University Of North Carolina At Chapel Hill | Bioorthogonal t cell receptor molecules and methods of making and using the same |
| EP4573114A4 (en) * | 2022-08-19 | 2026-07-29 | Memorial Sloan Kettering Cancer Center | T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES |
| US20260232734A1 (en) * | 2023-02-27 | 2026-08-13 | Adaptive Biotechnologies Corporation | Therapeutic T-Cell Receptors Targeting KRAS G12D |
| CN118924886A (zh) * | 2023-03-16 | 2024-11-12 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸的新用途 |
| CN118909132A (zh) * | 2023-05-06 | 2024-11-08 | 北京鼎成肽源生物技术有限公司 | 靶向kras g12v突变的tcr分子和细胞及其应用 |
| IL304887A (en) * | 2023-07-31 | 2025-02-01 | Yeda Res & Dev | T-cell receptor directed against RAS neoantigen |
| WO2025056659A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V AND G12C |
| WO2025056656A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V |
| WO2025189363A1 (zh) * | 2024-03-12 | 2025-09-18 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| WO2025240737A1 (en) * | 2024-05-16 | 2025-11-20 | Rutgers, The State University Of New Jersey | Methods of producing memory t cells in vitro and their use in immunotherapy |
| WO2025259799A2 (en) * | 2024-06-12 | 2025-12-18 | Biontech Us Inc. | T cell receptor compositions and methods of use thereof |
| EP4737476A1 (en) * | 2024-09-12 | 2026-05-06 | Medigene Immunotherapies GmbH | T-cell receptor variant against mkras 7-16 g12d |
| WO2026125390A1 (en) | 2024-12-09 | 2026-06-18 | Vib Vzw | Fthl17 immunogen and tcr |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| WO2013190090A1 (en) * | 2012-06-21 | 2013-12-27 | Philip Morris Products S.A. | Gene signatures for classifying and grading lung cancer |
| SG10201913978RA (en) * | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| EP3286222A4 (en) * | 2015-03-23 | 2018-08-08 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| JP6913032B2 (ja) * | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| TW201702272A (zh) * | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| SG11201808196UA (en) * | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| MX2020001879A (es) * | 2017-08-18 | 2020-07-29 | Gritstone Oncology Inc | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. |
| SG11202003798TA (en) * | 2017-10-27 | 2020-05-28 | Univ California | Targeted replacement of endogenous t cell receptors |
| TW202000907A (zh) * | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 共有抗原 |
-
2020
- 2020-11-13 CA CA3157411A patent/CA3157411A1/en active Pending
- 2020-11-13 CN CN202080085181.6A patent/CN115175934A/zh active Pending
- 2020-11-13 JP JP2022527937A patent/JP2023502625A/ja active Pending
- 2020-11-13 KR KR1020227019577A patent/KR20220098379A/ko active Pending
- 2020-11-13 IL IL292535A patent/IL292535A/en unknown
- 2020-11-13 WO PCT/US2020/060605 patent/WO2021097365A2/en not_active Ceased
- 2020-11-13 EP EP20886309.2A patent/EP4058484A4/en active Pending
- 2020-11-13 AU AU2020384374A patent/AU2020384374A1/en active Pending
-
2022
- 2022-05-13 US US17/744,354 patent/US20230041030A1/en active Pending
-
2025
- 2025-08-26 JP JP2025140331A patent/JP2025176716A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230041030A1 (en) | Antigen-binding proteins targeting shared neoantigens | |
| US11668705B2 (en) | General detection and isolation of specific cells by binding of labeled molecules | |
| CN110088133B (zh) | 抗独特型抗体及相关方法 | |
| AU2018250336B2 (en) | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods | |
| JP2021500852A5 (enExample) | ||
| US12139526B2 (en) | Modified chimeric receptors and related compositions and methods | |
| JP7611836B2 (ja) | 抗原特異的ｔ細胞の同定のための組成物と方法 | |
| US20140308259A1 (en) | Isolated b7-h4 specific compositions and methods of use thereof | |
| KR20200026805A (ko) | 세포 요법 및 면역조절 화합물의 조합 | |
| WO2019032927A1 (en) | METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF | |
| JP2017504324A5 (enExample) | ||
| WO2021092094A1 (en) | Antigen-binding proteins targeting shared neoantigens | |
| CN115768464A (zh) | 产生工程化记忆样nk细胞及其组合物的方法 | |
| CN113167796A (zh) | 对工程化细胞组合物进行质谱分析的方法 | |
| JP2009278927A (ja) | Ｔ細胞受容体を模倣する抗体断片及びその製造方法 | |
| US20250073323A1 (en) | Process for producing personalized cancer immunotherapy | |
| JP2025518203A (ja) | Ｍａｇｅ－ａ１特異的ｔｃｒ及びその用途 | |
| US20240180969A1 (en) | Polypeptides targeting hla-a*11 and methods of use thereof | |
| EP4737476A1 (en) | T-cell receptor variant against mkras 7-16 g12d | |
| King et al. | Bli dorp, I | |
| WO2026102194A1 (en) | Engineered immune proteins and uses thereof | |
| Wilson | Model systems for the retargeting of T cell-mediated immunity to tumor antigens | |
| CA3226437A1 (en) | Antigen binding proteins specifically binding ct45 |